Syneos Health Partners with Science 37® to Transform Clinical Trials – Increasing Speed and Diversity
March 29 2021 - 7:00AM
Syneos Health® (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization, and Science 37, the
industry’s only Decentralized Clinical Trial Operating
System™, today announced a strategic partnership to enable
enhanced decentralized clinical trial delivery. Together, Science
37 and Syneos Health will offer biopharmaceutical sponsors a
unified, seamless technology platform to streamline workflow
orchestration, real-world evidence generation, and data
harmonization.
Decentralized trials have been steadily increasing as sponsors
search for meaningful ways to drive efficiency, reduce cost,
increase speed and bring trials closer to the patient. Enabled by
digital technologies, these trials provide new ways to engage more
diverse, representative patient populations, reducing the burden
and increasing access for patients who previously couldn’t
participate in clinical trial research.
To bring clinical trials closer to the patient and transform
product development, Decentralized Solutions from Syneos Health
combines deep behavioral and therapeutic insights, agile
technologies, and operational excellence. Science 37’s premier
technology platform makes clinical trials virtual through its
flexible, on-demand network, comprised of patient communities,
telemedicine investigators, mobile nurses, remote coordinators, and
connected devices, strengthening clinical, and real-world
effectiveness and yielding high-quality data collection.
Science 37 is part of the Syneos Health Dynamic Assembly®
network. Dynamic Assembly is an open ecosystem of best-of-breed
data and technology collaborators committed to delivering
fit-for-purpose solutions designed to strategically address the
nuances of each customer engagement.
“Increasing clinical trial access and diversity is a scientific,
business and ethical imperative as we continually look for ways to
improve patient outcomes and eliminate healthcare disparities,”
said Alistair Macdonald, Chief Executive Officer of Syneos Health.
“Our powerful partnership with Science 37 adds their
industry-leading platform to our Decentralized Solutions and, when
combined with the mobile research nursing capabilities delivered
through our Illingworth Research team, we’re able to open new
pathways toward the long-sought goal of placing patients at the
center of clinical research.”
Through this partnership, Syneos Health becomes part of the
Science 37 CRO Certified program, designed to empower CROs with
access, training, and commercial support to successfully deliver
decentralized clinical studies at scale.
“Partnering with Syneos Health extends our mission to accelerate
research and enable universal patient and provider access with one
of the world’s most prolific providers of clinical research
services,” said David Coman, Chief Executive Officer of Science 37.
“Our technology will empower the Syneos Health decentralized trial
workflow, and our full Operating System will enable access to our
patient communities, telemedicine investigators, and remote
coordinator networks to harmonize and deliver complex decentralized
clinical and real-world studies.”
About Syneos HealthSyneos Health® (Nasdaq:SYNH)
is the only fully integrated biopharmaceutical solutions
organization. The Company, including a Contract Research
Organization (CRO) and Contract Commercial Organization (CCO), is
purpose-built to accelerate customer performance to address modern
market realities. We bring together approximately 25,000 clinical
and commercial minds with the ability to support customers in more
than 110 countries. Together we share insights, use the latest
technologies and apply advanced business practices to speed our
customers’ delivery of important therapies to patients.
To learn more about how we are Shortening the distance from lab
to life®, visit syneoshealth.com or subscribe to our podcast.
About Science 37Science 37 enables universal
access to clinical research—making it easier for patients and
providers to participate and accelerating the development of new
and innovative treatments that impact patient lives. With the
industry’s first and only, technology-first Decentralized Clinical
Trial Operating System™ (DCT OS), we enable workflow orchestration,
evidence generation and data harmonization on a unified, seamless
platform—configurable to enable any study and fused with our
expansive networks of telemedicine investigators, mobile nurses,
remote coordinators, patient communities and connected devices.
Learn more at Science 37, and follow Science 37 on Twitter,
LinkedIn, and Facebook.
|
|
|
Contacts |
|
|
Syneos Health |
|
|
Ronnie Speight |
|
Gary Gatyas |
Senior Vice President, Investor Relations |
|
Executive Director, External Communications |
+1 919 745 2745 |
|
+1 908 763 3428 |
Investor.Relations@syneoshealth.com |
|
gary.gatyas@syneoshealth.com |
|
|
|
Science 37Lawrence LloydPhone: +1 984 377
3737pr@science37.com |
|
|
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024